Candriam Luxembourg S.C.A. lowered its stake in Edwards Lifesciences Corporation (NYSE:EW) by 13.0% during the second quarter, Holdings Channel reports. The institutional investor owned 31,398 shares of the medical research company’s stock after selling 4,676 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Edwards Lifesciences Corporation were worth $3,713,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of EW. Egerton Capital UK LLP purchased a new position in Edwards Lifesciences Corporation during the second quarter valued at $217,805,000. Lockheed Martin Investment Management Co. boosted its position in Edwards Lifesciences Corporation by 86.7% in the second quarter. Lockheed Martin Investment Management Co. now owns 23,900 shares of the medical research company’s stock valued at $2,826,000 after buying an additional 11,100 shares in the last quarter. Johnston Asset Management LLC boosted its position in Edwards Lifesciences Corporation by 12.1% in the second quarter. Johnston Asset Management LLC now owns 379,351 shares of the medical research company’s stock valued at $44,854,000 after buying an additional 40,850 shares in the last quarter. CAPROCK Group Inc. purchased a new position in Edwards Lifesciences Corporation during the second quarter valued at $318,000. Finally, Honkamp Krueger Financial Services Inc. boosted its position in Edwards Lifesciences Corporation by 0.9% in the second quarter. Honkamp Krueger Financial Services Inc. now owns 11,946 shares of the medical research company’s stock valued at $1,412,000 after buying an additional 110 shares in the last quarter. 84.15% of the stock is owned by institutional investors.

Edwards Lifesciences Corporation (NYSE:EW) opened at 116.48 on Tuesday. The stock’s 50 day moving average price is $117.23 and its 200-day moving average price is $104.41. Edwards Lifesciences Corporation has a 52 week low of $81.12 and a 52 week high of $121.75. The company has a market cap of $24.60 billion, a price-to-earnings ratio of 35.33 and a beta of 0.63.

Edwards Lifesciences Corporation (NYSE:EW) last posted its quarterly earnings results on Wednesday, July 26th. The medical research company reported $1.08 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.20. The company had revenue of $842 million for the quarter, compared to analysts’ expectations of $839.16 million. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. Edwards Lifesciences Corporation’s revenue was up 10.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.76 EPS. On average, equities research analysts forecast that Edwards Lifesciences Corporation will post $3.64 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece was reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/08/08/candriam-luxembourg-s-c-a-sells-4676-shares-of-edwards-lifesciences-corporation-ew.html.

Several analysts recently issued reports on the company. Canaccord Genuity reiterated a “buy” rating and set a $155.00 target price (up previously from $150.00) on shares of Edwards Lifesciences Corporation in a report on Sunday, July 30th. Royal Bank Of Canada reiterated a “buy” rating and set a $130.00 target price on shares of Edwards Lifesciences Corporation in a report on Friday, July 28th. Cowen and Company reiterated an “outperform” rating and set a $135.00 target price (up previously from $130.00) on shares of Edwards Lifesciences Corporation in a report on Thursday, July 27th. Barclays PLC upped their target price on Edwards Lifesciences Corporation from $108.00 to $120.00 and gave the stock an “equal weight” rating in a report on Thursday, July 27th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $130.00 target price (up previously from $118.00) on shares of Edwards Lifesciences Corporation in a report on Thursday, July 27th. Five analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $121.13.

In other Edwards Lifesciences Corporation news, VP Patrick B. Verguet sold 22,631 shares of the business’s stock in a transaction on Friday, May 19th. The shares were sold at an average price of $113.16, for a total transaction of $2,560,923.96. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of the business’s stock in a transaction on Friday, July 28th. The shares were sold at an average price of $114.68, for a total transaction of $607,804.00. The disclosure for this sale can be found here. Insiders sold a total of 125,512 shares of company stock worth $14,460,159 in the last ninety days. 2.13% of the stock is currently owned by insiders.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.